Related Experiment Videos
Doxazosin: a new cytotoxic agent for prostate cancer?
1Department of Urology, Division of Medical Oncology and Division of Haematology, Ege University School of Medicine, Izmir, Turkey. cal@med.ege.edu.tr
Objective:
To determine the sensitivity of drug-resistant prostate cancer cell lines to doxazosin-mediated cell death, and the effects of combining doxazosin and chemotherapeutic agents on these cell lines. Materials and methods The cytotoxic effect of doxazosin was initially evaluated in the prostate carcinoma cell lines DU145 and PC-3. Doxazosin was combined either with adriamycin, etoposide or paclitaxel after its cytotoxic effects were detected in these cell lines. The tetrazolium dye (MTT) assay and trypan blue dye-exclusion tests were used to determine drug-mediated cytotoxicity. Experiments were performed at least three times and representative data are presented.
Results:
Both cell lines were sensitive to doxazosin-mediated cytotoxicity and the maximum cytotoxicity was achieved after 72 h. While cell death increased with increasing concentrations of doxazosin, 60 micromol/L doxazosin killed more than half of the cells in these cell lines. The combination of doxazosin with both adriamycin and etoposide resulted in significant synergistic cytotoxic activity at subtoxic concentrations of the drugs. Interestingly, the combination of doxazosin and paclitaxel resulted in antagonistic activity.
Conclusion:
Doxazosin-mediated cytotoxicity in the drug-resistant human prostate carcinoma cell lines was confirmed. Combinations of doxazosin with either adriamycin and etoposide, but not paclitaxel, had synergistic cytotoxic activity in these tumour cell lines. These results suggest that doxazosin could be a new cytotoxic agent, either used alone or combined, in the treatment of prostate cancer.
Insights
Doxazosin shows sensitivity in drug-resistant prostate cancer cells. Combining it with adriamycin or etoposide enhances cell death, but not with paclitaxel, suggesting its potential in prostate cancer treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Prostate cancer often develops resistance to chemotherapy.
- Identifying novel therapeutic agents for resistant prostate cancer is crucial.
Purpose of the Study:
- To assess doxazosin's sensitivity in drug-resistant prostate cancer cell lines.
- To evaluate the combined effects of doxazosin with chemotherapy agents.
Main Methods:
- Cytotoxicity of doxazosin was tested on DU145 and PC-3 cell lines.
- Doxazosin was combined with adriamycin, etoposide, and paclitaxel.
- Tetrazolium dye (MTT) assay and trypan blue dye-exclusion tests were employed.
Main Results:
- Doxazosin demonstrated significant cytotoxicity against both cell lines, with maximum effect at 72 hours.
- A combination of doxazosin with adriamycin or etoposide showed synergistic cytotoxic activity.
- Doxazosin combined with paclitaxel exhibited antagonistic activity.
Conclusions:
- Doxazosin is cytotoxic to drug-resistant prostate cancer cell lines.
- Synergistic effects were observed with adriamycin and etoposide, but not paclitaxel.
- Doxazosin presents potential as a standalone or combination therapy for prostate cancer.